Navigation Links
Healthpoint Biotherapeutics Acquires Regranex® Gel
Date:6/2/2011

FORT WORTH, Texas, June 2, 2011 /PRNewswire/ -- Healthpoint Biotherapeutics today announced that it has acquired Regranex® Gel, along with the corresponding intellectual property (including patents), from Systagenix. Terms of the deal were not disclosed.

"This acquisition is aligned with our strategic focus on building a portfolio of novel biopharmaceuticals for wound healing and tissue regeneration," said Travis E. Baugh, President and Chief Operating Officer of Healthpoint Biotherapeutics. "Moreover, Regranex® Gel is a good fit for our commercial organization, which has a well established record of successfully marketing biologics for wound care."

Regranex® Gel (0.01% Becaplermin) is a recombinant human platelet-derived growth factor (rhPDGF) and was the first biotechnology product approved for the treatment of lower extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue or beyond, and have adequate blood supply.  

About Regranex® Gel

Regranex® Gel (0.01% Becaplermin) is a recombinant human platelet-derived growth factor (rhPDGF) and was the first biotechnology product approved for the treatment of lower extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue or beyond, and have adequate blood supply, when used as an adjunct to, and not a substitute for, good ulcer care practices including initial sharp debridement, pressure relief and infection control. In clinical trials, Regranex® Gel in conjunction with good ulcer care demonstrated a statistically significant increase in the incidence of complete healing (defined as complete ulcer closure) versus placebo gel. It is not known if Regranex® Gelis effective for the treatment of pressure ulcers or ulcers that are due to poor blood flow (circulation). It is not known if Regranex® Gelis safe and effective in children under 16 years of age.

Important Safety Information<
'/>"/>

SOURCE Healthpoint Biotherapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Northwest Biotherapeutics to Present at American Society of Cell and Gene Therapy
2. Northwest Biotherapeutics and the Fraunhofer Institute for Cell Therapy and Immunology are Partnering for Clinical Trials and Compassionate Use Cases in Europe
3. Talecris Biotherapeutics Announces Results of Annual Stockholders Meeting
4. Talecris Biotherapeutics Announces First Quarter 2011 Results
5. Talecris Biotherapeutics to Report First Quarter 2011 Financial Results
6. Northwest Biotherapeutics Addresses Recent Market Activity
7. Talecris Biotherapeutics Announces Record Date for 2011 Annual Meeting of Shareholders
8. Talecris Biotherapeutics Announces Fourth Quarter and Full Year 2010 Results
9. Talecris Biotherapeutics Announces Teleconference and Webcast Information for Special Meeting of Shareholders
10. Talecris Biotherapeutics to Report Fourth Quarter and Full Year 2010 Financial Results
11. Talecris Biotherapeutics Announces Revised Record Date and Meeting Date for Special Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... (NASDAQ: ONCE ) announced today that members ... and Company Health Care Conference on Wednesday, March 4, ... Copley Place. To access the live webcast ... please visit the "Upcoming Events" section within the "News ... www.sparktx.com .  A replay of the webcast will ...
(Date:2/26/2015)... Feb. 26, 2015 Caris Life Sciences® ... the 2015 Genitourinary Cancers Symposium in ... utility of tumor profiling. Both studies utilized Caris ... service, to identify biomarkers that shed light on ... small cell bladder cancer (SCBC). ...
(Date:2/25/2015)... Calif. , Feb. 25, 2015 ... nootropic drink, is featured in this week,s Power ... cnbc.com/id/102454724 , to discuss the company,s traction and ... offering through the crowd funding site CircleUp. ... novel products that are validated by neurotechnology, while ...
(Date:2/25/2015)... 2015 Market Publishers Ltd is happy ... by 9Dimen Research have been recently uploaded to its ... Market Research Report . This research report provides wealth ... the world adhesive mortar industry as well as includes ... major regional markets. It focuses on the main regions ...
Breaking Biology Technology:Spark Therapeutics to Participate in the 35th Annual Cowen and Company Health Care Conference 2Tumor Profiling of Metastatic Prostate and Small Cell Bladder Cancers with Caris Molecular Intelligence Yields Insights into Novel and Conventional Therapeutic Options 2Tumor Profiling of Metastatic Prostate and Small Cell Bladder Cancers with Caris Molecular Intelligence Yields Insights into Novel and Conventional Therapeutic Options 3Tumor Profiling of Metastatic Prostate and Small Cell Bladder Cancers with Caris Molecular Intelligence Yields Insights into Novel and Conventional Therapeutic Options 4Tumor Profiling of Metastatic Prostate and Small Cell Bladder Cancers with Caris Molecular Intelligence Yields Insights into Novel and Conventional Therapeutic Options 5CNBC's Power Lunch Features Neurotechnology Start-up truBrain 2New Research Studies by 9Dimen Research Now Available at MarketPublishers.com 2New Research Studies by 9Dimen Research Now Available at MarketPublishers.com 3New Research Studies by 9Dimen Research Now Available at MarketPublishers.com 4
... , ... , , , ... samples of low cell numbers , , , ... cells have, for example,limited availability, quantity,and lifespan. Using the Agilent,2100 bioanalyzer ...
... , , , ... , , , , ... Agilent 2100 bioanalyzer can,be used to analyze apoptotic cell samples. Performance ... compared to,those obtained with a conventional flow cytometer. Histogram quality,of the ...
... , , , , ... The In Situ Cell Death Detection Kit has been designed as a precise, fast, and simple, ... the single-cell level in tissues. It is based on the so-called TUNEL, ... , , , , ...
Cached Biology Technology:Flow cytometric analysis of human,primary cells using the Agilent 2100,bioanalyzer and on-chip staining 2Flow cytometric analysis of human,primary cells using the Agilent 2100,bioanalyzer and on-chip staining 3Apoptosis detection by annexin V and,active caspase-3 with the Agilent 2100,bioanalyzer 2Apoptosis detection by annexin V and,active caspase-3 with the Agilent 2100,bioanalyzer 3Apoptosis detection by annexin V and,active caspase-3 with the Agilent 2100,bioanalyzer 4Apoptosis detection by annexin V and,active caspase-3 with the Agilent 2100,bioanalyzer 5Apoptosis detection by annexin V and,active caspase-3 with the Agilent 2100,bioanalyzer 6Apoptosis detection by annexin V and,active caspase-3 with the Agilent 2100,bioanalyzer 7Apoptosis detection by annexin V and,active caspase-3 with the Agilent 2100,bioanalyzer 8Apoptosis detection by annexin V and,active caspase-3 with the Agilent 2100,bioanalyzer 9In Situ Cell Death Detection Kit 2
(Date:1/22/2015)... , Jan. 13, 2015  Today, FreeWavz ( ... launched its crowdfunding campaign on Fundable, https://www.fundable.com/freewavz ... build of production capacity to meet customer demand. ... Photo - http://photos.prnewswire.com/prnh/20150113/168790 ...
(Date:1/22/2015)... Wis. , Jan. 15, 2015  BellBrook Labs, ... drug discovery, announced the launch of a TR-FRET ... the company,s Transcreener UDP Assay, a high throughput ... The new assay will allow for sensitive detection ...
(Date:1/22/2015)... , Jan. 20, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... commerce market, reports on the recent success of the Wocket™ smart wallet ... Wocket smart wallet was named as one of the "11 Hot ... "5 Best Products Launched At CES So Far" by Newseveryday.com and "The ...
Breaking Biology News(10 mins):FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3
... the Exploitation of Meteorological Satellites, agreed today that ... the last two Meteosat Second Generation (MSG) satellites, ... will provide control services during the critical launch ... the satellite from its initial position after separation ...
... 6 Foregoing food for a day each month ... the Church of Jesus Christ of Latter-Day Saints (LDS ... than other Americans, researchers reported at the American Heart ... receive a heart-protective benefit, and this appeared to also ...
... if the babies have a genetic variant that enhances their ... today in Proceedings of the National Academy of Sciences. ... in the control of fatty acid pathways, that may help ... promote the brain development that is associated with a higher ...
Cached Biology News:ESA to provide essential launch control services to EUMETSAT 2ESA to provide essential launch control services to EUMETSAT 3People who skip meals: are they better off? 2People who skip meals: are they better off? 3Breastfeeding boost IQ in infants with 'helpful' genetic variant 2